# Tan Thay

> Tan Thay is a Series A investor at Genting Berhad backing Health Care. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Genting Berhad
- Location: Kuala Lumpur, Malaysia
- Total investments: 2
- Last investment: Mar 2014
- Lead investor: 50%
- Last updated: Aug 2026

Tan Thay is a Series A investor at Genting Berhad in Kuala Lumpur focused on Health Care and Biotechnology. Tan Thay is the Founder & CEO of Genting Malaysia Berhad & he attended University of London.

## Contacts

5 contacts available for Tan Thay: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/tan-sri-lim-kok-thay?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Health Diagnostics | 2 | 100% |
| Genetics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Human Longevity | Human Longevity (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. Its business areas include the HLI Health Nucleus, a genomicpowered clinical research center that uses whole-genome sequence analysis, advanced clinical imaging, and innovative machine learning, along with curated personal health information to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. It was founded in 2013 and is headquartered in San Diego, California. | $80M | Series A | Mar 04, 2014 | https://healthnucleus100plus.com |
| Applied Proteomics | Applied Proteomics offers a protein biomarker discovery platform to advance the application of proteomics. The company is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. It has developed a proteomics platform solutionto make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.The company's platform combines improved instrumentation, faster computing, and extensive genome annotations with regimented standard operating procedures, extensive quality controls, and documented processes spanning hundreds of steps from sample collection to processing through informatics. | $28M | Series C | Aug 20, 2013 | http://www.appliedproteomics.com |

2 of 2 investments shown.

## Co-investors
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 1 deal together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 1 deal together
- [Illumina](https://shizune.co/investors/profile/illumina) — VC Fund, 1 deal together
- [OS Fund](https://shizune.co/investors/profile/os-fund) — VC Fund, 1 deal together
- [Viridos](https://shizune.co/investors/profile/synthetic-genomics) — VC Fund, 1 deal together
- [Threshold](https://shizune.co/investors/profile/threshold) — VC Fund, 1 deal together

## About Genting Berhad

VC Fund · Kuala Lumpur, Malaysia

Genting Berhad is a Malaysia-based company that enhances shareholder value and maintains long term growth in businesses.

5 contacts available at Genting Berhad.

| Name | Title | Profile |
| --- | --- | --- |
| KONG HAN TAN | Chief Operating Officer | https://shizune.co/investors/profile/tan-kong-han |
| Tan Thay | Chief Executive Officer | https://shizune.co/investors/profile/tan-sri-lim-kok-thay |
| Goh Lee Sian | Senior Vice President – Legal | — |
| Kong Han Tan | Chief Operating Officer | — |
| Woon Yoke Sun | Senior Vice President – Strategic Investment | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Tan Thay invest in?

Tan Thay invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series A and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Tan Thay?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Tan Thay last invest?

The most recent investment recorded for Tan Thay closed in Mar 2014. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co